HCP
AXSM icon

Hexagon Capital Partners’s Axsome Therapeutics AXSM Stock Holding History

Hexagon Capital Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13
Closed -$1.52K – 227
2025
Q1 		$1.52K Hold
13
– – ﹤0.01% 1464
2024
Q4 		$1.1K Buy
+13
New +$1.2K ﹤0.01% 1553

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Hexagon Capital Partners's AXSM Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 13 shares — an estimated $1.52K sold.

Hexagon Capital Partners first reported a position in AXSM in Q4 2024 and held it in 2 quarters. The position peaked at $1.52K in Q1 2025. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 13 Axsome Therapeutics shares in Q2 2025, an estimated $1.52K.
  • Hexagon Capital Partners first reported a position in Axsome Therapeutics in Q4 2024 and held it in 2 quarters.
  • Hexagon Capital Partners's Axsome Therapeutics position peaked at $1.52K in Q1 2025.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.